# CEVOLUTION (NCT07555938)

> Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07555938
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Multiple Myeloma
- Interventions: Cevostamab; Pomalidomide; Dexamethasone; Daratumumab; Elotuzumab; Carfilzomib
- Enrollment: 380
- Primary outcome: Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate
- Primary outcome: Progression-Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 3
- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cevolution-nct07555938